LHNVD-501

LHNVD-501 is a monoclonal antibody (biologic) being developed by **Longhorn Vaccines & Diagnostics** as a lead candidate for the prevention and treatment of bacterial infections and sepsis. The drug functions by targeting a highly conserved component of the bacterial cell wall that also acts as a toxin. This toxin is known to trigger inflammatory responses that can lead to chronic, debilitating diseases and systemic sepsis, either independently or through synergistic effects. By neutralizing this cell wall component, LHNVD-501 aims to mitigate inflammation and prevent the progression of severe bacterial complications.